Lexeo Therapeutics, Inc.
Net SellingLXEO·US·🇺🇸 US
23%buys·77%sales
163 transactions$52.6MTotal buys·12 buys
$1.6MTotal sells·41 sells
2626 insiders
Last: Nov 18, 2025
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Apr 6, 26 | Townsend Richard Nolan | Sell | $313K | |
| Nov 18, 25 | Robertson Jenny | Sell | $5K | |
| Nov 18, 25 | See Tai Sandi | Sell | $4K | |
| Nov 18, 25 | Adler Eric | Sell | $6K | |
| Nov 18, 25 | Townsend Richard Nolan | Sell | $10K | |
| Oct 17, 25 | Townsend Richard Nolan | Sell | $1K | |
| Oct 17, 25 | Townsend Richard Nolan | Sell | $116K | |
| Oct 17, 25 | Adler Eric | Sell | $30K | |
| Oct 17, 25 | Adler Eric | Sell | $363 | |
| Oct 17, 25 | Otero Jose Manuel | Sell | $229 |
Townsend Richard Nolan (CEO) recently executed a sell of $313K in Lexeo Therapeutics, Inc. shares on April 6, 2026. Overall insider sentiment is bearish (77% sales).
Lexeo Therapeutics, Inc. (LXEO) has recorded 163 insider operations, including 12 open-market purchases ($52.6M), 41 sales ($1.6M) and 110 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bearish (77% sales).
Lexeo Therapeutics, Inc. shows moderate insider activity with 7 active months out of the last 12, typical of a company whose trading windows are concentrated around financial disclosures.
Among the most active insiders are Townsend Richard Nolan (CEO), Rasbach Kyle (CFO) & Tamayo Louis Edward (CFO), with respectively 43, 2, 2 transactions.
Across all 164 recorded transactions, the breakdown by type is: exercise (62, 38%), grant (48, 29%), sales (42, 26%), buys (12, 7%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Lexeo Therapeutics, Inc. has recorded 163 insider operations in total, including 12 open-market purchases ($52.6M), 41 sales ($1.6M) and 110 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on November 18, 2025.
Insiders at Lexeo Therapeutics, Inc. are currently net sellers, with 23% purchases and 77% sales across all reported transactions. Total buy volume is $52.6M versus $1.6M in sales, indicating a bearish insider sentiment.
InsiderLens tracks 26 insiders at Lexeo Therapeutics, Inc. (LXEO). Townsend Richard Nolan (CEO, 43 tx), Rasbach Kyle (CFO, 2 tx), Tamayo Louis Edward (CFO, 2 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for LXEO is bearish, based on a 23% buy ratio across 53 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Lexeo Therapeutics, Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.